Literature DB >> 18790008

Protective effect of estrogen in endothelin-induced middle cerebral artery occlusion in female rats.

Michele L Glendenning1, Tara Lovekamp-Swan, Derek A Schreihofer.   

Abstract

Estrogen is a powerful endogenous and exogenous neuroprotective agent in animal models of brain injury, including focal cerebral ischemia. Although this protection has been demonstrated in several different treatment and injury paradigms, it has not been demonstrated in focal cerebral ischemia induced by intraparenchymal endothelin-1 injection, a model with many advantages over other models of experimental focal ischemia. Reproductively mature female Sprague-Dawley rats were ovariectomized and divided into placebo and estradiol-treated groups. Two weeks later, halothane-anesthetized rats underwent middle cerebral artery (MCA) occlusion by interparenchymal stereotactic injection of the potent vasoconstrictor endothelin 1 (180pmoles/2microl) near the middle cerebral artery. Laser-Doppler flowmetry (LDF) revealed similar reductions in cerebral blood flow in both groups. Animals were behaviorally evaluated before, and 2 days after, stroke induction, and infarct size was evaluated. In agreement with other models, estrogen treatment significantly reduced infarct size evaluated by both TTC and Fluoro-Jade staining and behavioral deficits associated with stroke. Stroke size was significantly correlated with LDF in both groups, suggesting that cranial perfusion measures can enhance success in this model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790008      PMCID: PMC2617785          DOI: 10.1016/j.neulet.2008.09.006

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  44 in total

1.  LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia.

Authors:  M J O'Neill; C A Hicks; M A Ward; D J Osborne; G Wishart; K S Mathews; D P McLaughlin; J A Stamford; D R McCarty; K E Patrick; C Roman; J H Fleisch; J Gilmore; J R Boot
Journal:  Brain Res       Date:  2001-01-05       Impact factor: 3.252

Review 2.  Estrogen and stroke: a balanced analysis.

Authors:  Patricia D Hurn; Lawrence M Brass
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

3.  A comparison of long-term functional outcome after 2 middle cerebral artery occlusion models in rats.

Authors:  R L Roof; G P Schielke; X Ren; E D Hall
Journal:  Stroke       Date:  2001-11       Impact factor: 7.914

4.  Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats.

Authors:  Y Matsuo; M Ninomiya; M Fujimoto
Journal:  Stroke       Date:  2001-09       Impact factor: 7.914

Review 5.  Estradiol is a neuroprotective factor in in vivo and in vitro models of brain injury.

Authors:  P M Wise; D B Dubal; M E Wilson; S W Rau
Journal:  J Neurocytol       Date:  2000 May-Jun

6.  Delayed minocycline treatment reduces long-term functional deficits and histological injury in a rodent model of focal ischemia.

Authors:  K A Hewlett; D Corbett
Journal:  Neuroscience       Date:  2006-05-11       Impact factor: 3.590

7.  A new reproducible focal cerebral ischemia model by introduction of polyvinylsiloxane into the middle cerebral artery: a comparison study.

Authors:  Yi Yang; Tao Yang; Qiu Li; Chen Xu Wang; Ashfaq Shuaib
Journal:  J Neurosci Methods       Date:  2002-08-30       Impact factor: 2.390

8.  17 Beta-estradiol regulates the expression of endothelin receptor type B in the heart.

Authors:  Simone Nuedling; Martin van Eickels; Axel Alléra; Pieter Doevendans; Rainer Meyer; Hans Vetter; Christian Grohé
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

9.  Mechanisms of 17beta-estradiol on the production of ET-1 in ovariectomized rats.

Authors:  Zhi Tan; Ting-Huai Wang; Dang Yang; Xaio-Dong Fu; Jing-Yun Pan
Journal:  Life Sci       Date:  2003-10-10       Impact factor: 5.037

Review 10.  Estrogen and ischemic neuroprotection: an integrated view.

Authors:  Louise D McCullough; Patricia D Hurn
Journal:  Trends Endocrinol Metab       Date:  2003-07       Impact factor: 12.015

View more
  7 in total

Review 1.  Sex hormones and stroke: Beyond estrogens.

Authors:  Farida Sohrabji; Andre Okoreeh; Aditya Panta
Journal:  Horm Behav       Date:  2018-11-20       Impact factor: 3.587

2.  Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a.

Authors:  Irène R Chassagnon; Claudia A McCarthy; Yanni K-Y Chin; Sandy S Pineda; Angelo Keramidas; Mehdi Mobli; Vi Pham; T Michael De Silva; Joseph W Lynch; Robert E Widdop; Lachlan D Rash; Glenn F King
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

Review 3.  Neuroprotective action of acute estrogens: animal models of brain ischemia and clinical implications.

Authors:  Tomoko Inagaki; Anne M Etgen
Journal:  Steroids       Date:  2013-02-04       Impact factor: 2.668

4.  Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.

Authors:  Adam P Mecca; Timothy E O'Connor; Michael J Katovich; Colin Sumners
Journal:  Exp Physiol       Date:  2009-05-08       Impact factor: 2.969

5.  Chronic estradiol treatment increases CA1 cell survival but does not improve visual or spatial recognition memory after global ischemia in middle-aged female rats.

Authors:  M De Butte-Smith; M Gulinello; R S Zukin; A M Etgen
Journal:  Horm Behav       Date:  2008-12-14       Impact factor: 3.587

6.  Impact of methodology on estrogens' effects on cerebral ischemia in rats: an updated meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg
Journal:  BMC Neurosci       Date:  2014-02-04       Impact factor: 3.288

Review 7.  An Evidence-Based Review of Related Metabolites and Metabolic Network Research on Cerebral Ischemia.

Authors:  Mengting Liu; Liying Tang; Xin Liu; Jing Fang; Hao Zhan; Hongwei Wu; Hongjun Yang
Journal:  Oxid Med Cell Longev       Date:  2016-05-05       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.